Allergic Eye Disease Tear Mediators
Information source: University of Wisconsin, Madison
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Allergic Eye Disease
Intervention: olopatadine (Drug)
Phase: N/A
Status: Recruiting
Sponsored by: University of Wisconsin, Madison Official(s) and/or principal investigator(s):
Neal P Barney, MD, Principal Investigator, Affiliation: University of Wisconsin, Madison
Summary
The purpose of the research is to determine which inflammatory substances are involved in
causing allergic symptoms in the eye. Allergic conjunctivitis is a common problem with
symptoms of temporary redness, itching, tearing, and swelling of the eyes. Substances
released by cells in the affected tissues cause allergic reactions in the eye and elsewhere
in the body.
Clinical Details
Official title: Expression of Inflammatory Mediators in Allergic Conjunctivitis
Study design: Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science
Primary outcome: tear cytokine concentrations with and without treatment
Secondary outcome: conjunctival epithelial cell surface marker measured with and without treatment
Detailed description:
Ocular allergies are extremely common, affecting up to 80 million people in the USA. Our
research question is:
Are there differences in inflammatory mediators and cell surface activation markers in
patients undergoing seasonal allergic conjunctivitis compared to those with sight
threatening disease such as Atopic Keratoconjunctivitis (AKC) and will the use of the
anti-allergy eye drop, PATANOL® (olopatadine hydrochloride) affect these parameters?
Experimental Design:
Ocular surface cells (by impression cytology) and tears (via capillary tube) are collected
from allergic, non-allergic, and AKC subjects undergoing an reaction induced either by
seasonal allergen or topical allergen provocation (specificity and dose determined via skin
testing). Ocular surface cells are evaluated for surface activation markers. Tears are
evaluated for mediator content. Tears are also incubated with peripheral blood eosinophils
and lymphocytes to see effects on adhesion to conjunctival epithelial cells.
Eligibility
Minimum age: 18 Years.
Maximum age: 65 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Skin test positive
- Able to put drops in eyes
- Able to have tears collected
Locations and Contacts
University of Wisconsin, Madison, Wisconsin 53705, United States; Recruiting
Neal P Barney, MD, Phone: 608-263-7681, Email: npbarney@wisc.edu
Jim Stahl, PhD, Phone: 608-263-6177, Email: jlstahl@medicine.wisc.edu
Neal P Barney, MD, Principal Investigator
Frank M Graziano, MD PhD, Sub-Investigator
Ellen B Cook, PhD, Sub-Investigator
Jim Stahl, PhD, Sub-Investigator
Additional Information
Related publications: Cook EB. Tear cytokines in acute and chronic ocular allergic inflammation. Curr Opin Allergy Clin Immunol. 2004 Oct;4(5):441-5. Review.
Starting date: September 2000
Last updated: October 30, 2008
|
